10 years at the heart of the matter
STORZ MEDICAL convinces experts at the ESC Congress in Barcelona of the advantages of CSWT – Cardiac Shock Wave Therapy

Powerful and innovative: STORZ MEDICAL AG, Switzerland put in an extremely successful appearance at the internationally renowned European Society of Cardiology (ESC) Congress that took place in Barcelona from August 29 to September 2, 2009. Dr. Ernst H. Marlinghaus, Head of Project and Development at STORZ MEDICAL, pioneers and global leaders in the area of cardiac shock wave therapy (CSWT), demonstrated the scientific and technical cutting-edge technology to an audience of more than 30,000 visitors at the congress and managed to gain a large number of new clients.

At the heart of the demonstration was the innovative strength of the MODULITH® SLC's electromagnetic source, the convincing in-line ALOKA ProSound 6 ultrasound system, the quality of the treatment results, and above all, more than ten years of experience in the area of clinical cardiac shock wave therapy at STORZ MEDICAL.

Moments to savour: The success of our »CSWT Lunch Time Workshops«

Prominence and tradition in the area of shock wave therapy and trust in the STORZ MEDICAL brand were instrumental in attracting unusually large numbers of congress visitors to the STORZ MEDICAL stand where they were provided with information about the trendsetting therapeutic possibilities of the MODULITH^® SLC. More than 500 cardiologists took part in the CSWT »Lunch Time Workshops« on »Non-invasive revascularisation by CSWT«.

However, it was the well-attended presentations by Professor Bernhard Meier, Director and Head of Cardiology at the University Hospital in Bern, Switzerland, on the »Treatment options for non-revascularisable angina pectoris« and Professor Shimokawa of the Japanese Tohoku University on the results and status of the pilot und placebo-controlled clinical study »Non-invasive revascularisation by CSWT in chronic ischemia, animal and clinical studies« as well as Dr. A. Khattab, Bad Segeberg, Germany and University Hospital Bern, Switzerland on »CSWT in every day practice« that clearly demonstrated the impact of STORZ MEDICAL shock wave therapy on cardiac disease.

The MODULITH^® SLC from STORZ MEDICAL has become an integral and routine feature of cardiology departments in many countries all over the world, making STORZ MEDICAL the leading company in non-invasive revascularisation.

There were other inspirational presentations that focussed on CSWT. Dr. A. Gutersohn, Asklepios Clinic, Hamburg, Germany, presented a paper dealing with the long-term positive effects of CSWT after five years, and Dr. J.-P. Schmid, University Hospital Bern, Switzerland won over his audience with a presentation on the results of the first placebo-controlled clinical study: the placebo group showed no effect, whereas the quantitative data from the spiroergometry and the data from the SF-36 questionnaire were statistically significantly positive.

Treatment options for non-revascularisable angina pectoris
Bernhard Meier, MD, Professor and Head of Cardiology, Department of Cardiology, Swiss Cardiovascular Center Bern, University Hospital Bern, Switzerland

Non-invasive revascularisation by CSWT in chronic ischemia, animal and clinical studies Hiroaki Shimokawa, MD, PhD, Professor and Chairman, Department of Cardiovascular Medicine, Tohoku University, Graduate School of Medicine, Sendai, Japan

CSWT in every day practice
Ahmed Khattab, MD, Department of Cardiology, Segeberger Kliniken, Bad Segeberg, Germany, now: Department of Cardiology, Swiss Cardiovascular Center Bern, University Hospital Bern, Switzerland

CSWT – prospective, randomised, placebo-controlled study
Jean-Paul Schmid, MD, Department of Cardiology, Swiss Cardiovascular Center Bern, University Hospital Bern, Switzerland

CSWT – 5 year follow-up
Achim Gutersohn, MD, Department of Cardiology, Asklepios Clinic, Hamburg, Germany